$5.86
−2.50%Oct 14, 2026, 11:30 UTC
Profound Medical announced that five abstracts presented at the Profound Medical Corp. support the real-world performance, clinical differentiation and platform expansion potential of its TULSA Procedure using the TULSA-PRO system.
Source:Oct 9, 2026, 12:45 UTC
Profound Medical Corp. shares rose 21.7% in the last trading session on above-average volume.
Source:Oct 7, 2026, 20:15 UTC
Profound Medical Corp. announced preliminary third-quarter 2026 revenue of $9.8 million to $10.0 million, approximately 45% to 47% above Bloomberg LP analyst consensus.
Source:Sep 3, 2026, 11:11 UTC
Profound Medical Corp. announced a role change for Mathieu Burtnyk to Chief Technology Officer, effective September 1, 2026.
Sep 1, 2026, 12:00 UTC
Profound Medical Corp. appointed Richard Fabian as its new President, effective immediately.
Source:Aug 17, 2026, 12:30 UTC
Profound introduced new real-time interventional MRI software (TDC) that enables customers to perform up to 6 TULSA Procedures per system per day.
Source:Aug 17, 2026, 00:00 UTC
Profound Medical Corp. announced that Rashed Dewan resigned as Chief Financial Officer, effective August 14, 2026, and appointed Matthew Sobczyk as Interim Chief Financial Officer.
Aug 14, 2026, 20:30 UTC
Profound Medical Corp. promoted Matthew Sobczyk from Corporate Controller to Interim Chief Financial Officer, effective immediately, succeeding Rashed Dewan who stepped down as CFO.
Source:Aug 7, 2026, 03:36 UTC
Profound Medical reported Q2 2026 earnings of $0.26 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share, and compared to a loss of $0.52 per share a year ago.
Source: